Post hoc analysis explores treatment response factors in UC patients, suggesting personalized management strategies for better outcomes.
Introduction: Identifying patient (pt) populations and long-term treatment response factors can enable personalised management strategies in ulcerative colitis (UC). Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC.
No takes yet. Share an insight, caveat, or question.
Sollacher et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: